{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-24-000069","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.749834+00:00","generated_at":"2026-06-01T00:01:32.724526+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Avanos Medical appoints Indrani Franchini to Board of Directors, effective July 1, 2024","bullets":["Appointment fills a vacancy; Franchini will serve on Audit and Compliance Committees.","Compensation includes $70,000 annual cash retainer, $12,500 Audit, $7,500 Compliance, and $190,000 RSU grant.","Board now comprises 6 directors (5 independent) with 3 women, 2 ethnically diverse.","Franchini previously EVP/CLO at Alnylam, EVP/CCO at Alexion, and roles at Hess and Pfizer."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-24-000069","json":"https://secwatch.observer/filing/0001606498-24-000069.json","markdown":"https://secwatch.observer/filing/0001606498-24-000069.md","text":"https://secwatch.observer/filing/0001606498-24-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649824000069/0001606498-24-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649824000069/avns-20240628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:01:32.724526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51f4f406d4","claim":"Indrani Franchini was appointed as Director at AVANOS MEDICAL, INC..","evidence_excerpt":"On June 28, 2024, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Indrani Franchini to the Board, effective July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649824000069/0001606498-24-000069-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}